MX2022013920A - Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. - Google Patents
Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.Info
- Publication number
- MX2022013920A MX2022013920A MX2022013920A MX2022013920A MX2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A MX 2022013920 A MX2022013920 A MX 2022013920A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- associated antigen
- tumor associated
- antigen antibodies
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021215P | 2020-05-07 | 2020-05-07 | |
| US202062706131P | 2020-08-03 | 2020-08-03 | |
| US202063198420P | 2020-10-16 | 2020-10-16 | |
| US202063131394P | 2020-12-29 | 2020-12-29 | |
| PCT/US2021/031055 WO2021226321A2 (en) | 2020-05-07 | 2021-05-06 | Anti-tumor associated antigen antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013920A true MX2022013920A (es) | 2022-11-30 |
Family
ID=78468388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013920A MX2022013920A (es) | 2020-05-07 | 2021-05-06 | Anticuerpos anti-antigeno asociado con tumor y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220107A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146702A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7821121B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230007452A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021267893A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020716A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173176A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297955A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013920A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021226321A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| EP4605425A1 (en) * | 2022-10-18 | 2025-08-27 | Zymeworks BC Inc. | Antibody-drug conjugates targeting glypican-3 and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
| AU2008275985B2 (en) * | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| US9206257B2 (en) * | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| JP2017522861A (ja) * | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW201713700A (zh) * | 2015-05-27 | 2017-04-16 | 台灣泰福生技股份有限公司 | 抗glypican-3抗體及其用於診斷及治療癌症之用途 |
| EP3431102A4 (en) * | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| CN109153719B (zh) * | 2016-03-15 | 2022-12-30 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| CN118421557A (zh) * | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| EP3551220B1 (en) * | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EP3615574B1 (en) * | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| JP7382922B2 (ja) * | 2017-09-20 | 2023-11-17 | 中外製薬株式会社 | Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| CN111040036B (zh) * | 2018-10-12 | 2023-10-20 | 上海卡智生物技术有限公司 | 抗gpc3单克隆抗体、由其修饰的免疫效应细胞及其应用 |
-
2021
- 2021-05-06 MX MX2022013920A patent/MX2022013920A/es unknown
- 2021-05-06 CN CN202180032994.3A patent/CN115515981A/zh active Pending
- 2021-05-06 IL IL297955A patent/IL297955A/en unknown
- 2021-05-06 CA CA3173176A patent/CA3173176A1/en active Pending
- 2021-05-06 JP JP2022567223A patent/JP7821121B2/ja active Active
- 2021-05-06 AU AU2021267893A patent/AU2021267893A1/en active Pending
- 2021-05-06 EP EP21800926.4A patent/EP4146702A4/en active Pending
- 2021-05-06 WO PCT/US2021/031055 patent/WO2021226321A2/en not_active Ceased
- 2021-05-06 US US17/997,755 patent/US20230220107A1/en active Pending
- 2021-05-06 KR KR1020227041924A patent/KR20230007452A/ko active Pending
- 2021-05-06 BR BR112022020716A patent/BR112022020716A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL297955A (en) | 2023-01-01 |
| AU2021267893A1 (en) | 2022-11-03 |
| JP2023525991A (ja) | 2023-06-20 |
| BR112022020716A2 (pt) | 2022-11-29 |
| EP4146702A4 (en) | 2024-07-10 |
| CN115515981A (zh) | 2022-12-23 |
| JP7821121B2 (ja) | 2026-02-26 |
| EP4146702A2 (en) | 2023-03-15 |
| CA3173176A1 (en) | 2021-11-11 |
| KR20230007452A (ko) | 2023-01-12 |
| WO2021226321A3 (en) | 2021-12-16 |
| WO2021226321A2 (en) | 2021-11-11 |
| US20230220107A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| ZA202006318B (en) | Anti-dll3 antibodies and uses thereof | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2022010664A (es) | Materiales y métodos para modular una respuesta inmunitaria. | |
| MX2023002945A (es) | Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas. | |
| WO2021227307A8 (zh) | 抗cd73抗体及其用途 | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| PH12022553035A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| ZA202302392B (en) | Antibodies against ilt2 and use thereof | |
| WO2021226321A3 (en) | Anti-tumor associated antigen antibodies and uses thereof | |
| EP4691569A3 (en) | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2023002948A (es) | Métodos y composiciones para modular la inmunidad mediada por cadena beta. | |
| MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| WO2023177974A3 (en) | Anti-mesothelin antibodies and uses thereof | |
| MX2024011805A (es) | Nuevos anticuerpos anti-fgfr2 | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| AU2018345715A8 (en) | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
| EA202092123A1 (ru) | Антитела против клаудина 18.2 и их применения | |
| MX2024009726A (es) | Anticuerpos anti-il13ra2 y usos de estos. |